Drug Safety Should Focus On “Maximizing Benefit,” Not Just “Minimizing Risk” – FDA’s Goodman

Agency’s acting chief scientist emphasizes need for communication “in the face of uncertainty” and rejects the “either/or” choice of personalized medicine versus comparative effectiveness.